In cases presenting T172-phosphorylated CDK4 (excluding the rare possibility of p16 loss co-occurring with RB deficiency), tumors are expected to depend on the CDK4 activity and CDK4/6i might represent a relevant therapy when required. This evidence concerns the gene CDK4 and hyperinsulinemic hypoglycemia, familial, 4.